The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
Subscribe To Our Newsletter & Stay Updated
